Arcus Biosciences, Inc.
HealthcareNYSE:RCUS · New York Stock Exchange
+$0.50 today
Vol 1.23M · Avg 1.29M
Filings
Ground the analysis in primary documents
Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.
Price History
Dividend-adjusted closing price
Change
+157.58%
Period High
$26.62
Period Low
$7.95
Latest
$23.80
SEC Filings
Recent regulatory filings
No filings found.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
What is the latest RCUS filing?
The latest filing shown is 4 dated Jun 12, 2026.
How many recent filings does RCUS have?
Intrinsic Alpha currently shows 20 recent filings for RCUS.
Explore More
Continue the stock analysis
Jump to another research area for this company.